RxDoctor Payments Data

Anil Patel, MD

Cardiovascular Disease · San Diego, CANPI 1386746931

Payments from drug & device makers

$5,127in general payments, 2019–2025

Across 285 payments — averaging $17.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$634
  • E.r. Squibb & Sons, L.L.C.$562
  • Boston Scientific$531
  • Pfizer$502
  • Novartis$447
  • Amgen$249
  • plus $2K from 30 others

What the payments were for

  • Food & beverage$5,116100%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,127 in reported general payments places this provider in the 60th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$579,641
Medicare patients
3,408
Services billed
11,318

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban859$919,800
XareltoRivaroxaban162$186,149
EntrestoSacubitril/Valsartan146$137,593
CamzyosMavacamten15$122,057
JardianceEmpagliflozin88$94,599
MultaqDronedarone Hcl54$71,187
Repatha SureclickEvolocumab80$56,740
FarxigaDapagliflozin Propanediol32$49,254
Praluent PenAlirocumab28$26,957
BrilintaTicagrelor16$10,384
Rosuvastatin Calcium345$6,419
Carvedilol650$6,136
Metoprolol Succinate361$5,507
Ezetimibe130$5,054
Ranolazine ErRanolazine25$5,025

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$502$919,800859 claims
Johnson & JohnsonXarelto$634$186,149162 claims
NovartisEntresto$447$137,593146 claims
E.r. Squibb & Sons, L.L.C.Camzyos$562$122,05715 claims
Boehringer IngelheimJardiance$130$94,59988 claims
Sanofi-aventis U.S. LLCMultaq$63$71,18754 claims
AstraZenecaFarxiga, Brilinta$245$59,63848 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →